ASTRAZENECA PLC (ZEG.DE) Stock Price, Quote, News and Overview
FRA:ZEG - Deutsche Boerse Ag - GB0009895292 - Common Stock - Currency: EUR
ZEG.DE Quote, Performance and Key Statistics
FRA:ZEG (5/21/2025, 7:00:00 PM)
124.75
+0.6 (+0.48%)
The current stock price of ZEG.DE is 124.75 EUR. In the past month the price increased by 5.23%. In the past year, price decreased by -13.67%.
ZEG.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1LLY.MI | ELI LILLY & CO | 53.59 | 617.24B | ||
| LLY.DE | ELI LILLY & CO | 52.16 | 600.74B | ||
| JNJ.DE | JOHNSON & JOHNSON | 15.28 | 326.41B | ||
| 1JNJ.MI | JOHNSON & JOHNSON | 15.22 | 325.25B | ||
| NOV.DE | NOVO NORDISK A/S-B | 19.16 | 261.90B | ||
| RHO.DE | ROCHE HOLDING AG-BR | 14.93 | 242.78B | ||
| 1SAN.MI | SANOFI | 13.96 | 230.07B | ||
| SNW.DE | SANOFI | 13.91 | 229.11B | ||
| SAN.PA | SANOFI | 13.81 | 227.57B | ||
| NOT.DE | NOVARTIS AG-REG | 13.69 | 197.94B | ||
| 1MRKX.MI | MERCK & CO. INC. | 10.07 | 174.39B | ||
| 6MK.DE | MERCK & CO. INC. | 10 | 173.13B |
Related stock screener links
About ZEG.DE
Company Profile
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. The company also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.
Company Info
ASTRAZENECA PLC
1 Francis Crick Avenue, Cambridge Biomedical Campus
CAMBRIDGE CAMBRIDGESHIRE GB
Employees: 94300
Phone: 442073045000
ASTRAZENECA PLC / ZEG.DE FAQ
What is the stock price of ASTRAZENECA PLC today?
The current stock price of ZEG.DE is 124.75 EUR. The price increased by 0.48% in the last trading session.
What is the ticker symbol for ASTRAZENECA PLC stock?
The exchange symbol of ASTRAZENECA PLC is ZEG and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is ZEG.DE stock listed?
ZEG.DE stock is listed on the Deutsche Boerse Ag exchange.
What is the price forecast or stock price prediction for ASTRAZENECA PLC stock?
35 analysts have analysed ZEG.DE and the average price target is 163.45 EUR. This implies a price increase of 31.02% is expected in the next year compared to the current price of 124.75. Check the ASTRAZENECA PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ASTRAZENECA PLC worth?
ASTRAZENECA PLC (ZEG.DE) has a market capitalization of 386.77B EUR. This makes ZEG.DE a Mega Cap stock.
How many employees does ASTRAZENECA PLC have?
ASTRAZENECA PLC (ZEG.DE) currently has 94300 employees.
What are the support and resistance levels for ASTRAZENECA PLC (ZEG.DE) stock?
ASTRAZENECA PLC (ZEG.DE) has a support level at 123.2 and a resistance level at 126.4. Check the full technical report for a detailed analysis of ZEG.DE support and resistance levels.
Is ASTRAZENECA PLC (ZEG.DE) expected to grow?
The Revenue of ASTRAZENECA PLC (ZEG.DE) is expected to grow by 8.37% in the next year. Check the estimates tab for more information on the ZEG.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ASTRAZENECA PLC (ZEG.DE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ZEG.DE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ZEG.DE, evaluating the profitability, health, valuation and growth aspects
- ASTRAZENECA PLC (ZEG.DE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ASTRAZENECA PLC (ZEG.DE) Sales and EPS estimates to see what analysts future expectations are.
- ASTRAZENECA PLC (ZEG.DE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ASTRAZENECA PLC (ZEG.DE) Insider and Institutional Ownership to learn about the owners and their transactions.
- ASTRAZENECA PLC (ZEG.DE) Stock Chart to make your own analysis
- ASTRAZENECA PLC (ZEG.DE) Latest news and press-releases to stay up to date.
Does ASTRAZENECA PLC (ZEG.DE) stock pay dividends?
ASTRAZENECA PLC (ZEG.DE) has a dividend yield of 2.42%. The yearly dividend amount is currently 2.67. Check the full fundamental report for a detailed analysis of ZEG.DE dividend history, reliability and sustainability.
When does ASTRAZENECA PLC (ZEG.DE) report earnings?
ASTRAZENECA PLC (ZEG.DE) will report earnings on 2025-07-29, before the market open.
What is the Price/Earnings (PE) ratio of ASTRAZENECA PLC (ZEG.DE)?
The PE ratio for ASTRAZENECA PLC (ZEG.DE) is 19.1. This is based on the reported non-GAAP earnings per share of 6.53 and the current share price of 124.75 EUR. Check the full fundamental report for a full analysis of the valuation metrics for ZEG.DE.
ZEG.DE Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ZEG.DE. When comparing the yearly performance of all stocks, ZEG.DE is a bad performer in the overall market: 85.68% of all stocks are doing better.
ZEG.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to ZEG.DE. While ZEG.DE belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
ZEG.DE Financial Highlights
Over the last trailing twelve months ZEG.DE reported a non-GAAP Earnings per Share(EPS) of 6.53.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 14.14% | ||
| ROA | 7.31% | ||
| ROE | 18.94% | ||
| Debt/Equity | 0.71 |
ZEG.DE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to ZEG.DE. The Buy consensus is the average rating of analysts ratings from 35 analysts.
For the next year, analysts expect an EPS growth of 12.48% and a revenue growth 8.37% for ZEG.DE